What is Ivermectin?
Ivermectin is a small but mighty molecule that has quietly revolutionized medicine and agriculture over the past four decades. Discovered in the late 1970s by Japanese microbiologist Satoshi Ōmura and American biochemist William C. Campbell, it sprang from soil-dwelling bacteria (Streptomyces avermitilis) into a global superstar—so much so that its discoverers shared the 2015 Nobel Prize in Physiology or Medicine. At heart, ivermectin is a macrocyclic lactone: a ring-shaped chemical scaffold that’s both potent and remarkably selective in its biological targets.
In people and animals, ivermectin’s superpower lies in paralyzing parasites. It binds to certain ion channels—chiefly glutamate-gated chloride channels in worms and insects—causing an influx of chloride ions, rapid hyperpolarization of nerve and muscle cells, and ultimately paralysis of the invader. This paralysis stops the parasites from feeding, migrating, or reproducing, allowing the host’s immune system to clear the infection. Thanks to its safety profile and broad-spectrum action, ivermectin has been deployed to combat river blindness, lymphatic filariasis, scabies, and a host of livestock pests, saving countless lives and livelihoods.
But what predictions dose Zygos have for its biological effects?
An Opioid-agonist?
Zygos strikingly predicts the Ivermectin could possibly be having some opioidergic effects by binding to the kappa-opioid receptor. But does this prediction hold water? A 2024 study by Manavi et al. suggests that it does. [1] Researchers induced status epilepticus (SE) in rats by first priming the animals with lithium chloride and then triggering seizures with pilocarpine. Thirty minutes before this seizure onslaught, the team administered ivermectin at doses ranging from tiny (0.3 mg/kg) to substantial (10 mg/kg). It turned out that the mid-range doses – 3, 5, and 10 mg/kg – significantly quelled seizure severity, as measured by the classical Racine scale.
They discovered that blocking KATP channels with glibenclamide or blocking opioid receptors with naltrexone blunted ivermectin’s protective power. In contrast, diazepam, nicorandil, morphine, and the NO inhibitors all boosted seizure suppression when given alongside a sub-effective dose of ivermectin. In other words, ivermectin seems to orchestrate a symphony of calming signals – enhancing GABA, dialing in opioid feedback, tempering NO, and tweaking KATP channels – to keep seizures in check.
Finally, molecular assays revealed that ivermectin didn’t just stop seizures – it also dampened the inflammatory storm that typically follows SE. Levels of the pro-inflammatory cytokines TNF-α and IL-1β fell, while GABAA receptor expression in the hippocampus rebounded toward normal.
Taken together, these findings cast ivermectin in a whole new light: not just as an antiparasitic, but as a multi-pronged seizure-buster that leverages the brain’s own inhibitory and anti-inflammatory machinery. While further studies will be needed to gauge safety and efficacy in humans, the study shines a spotlight on the untapped potential of repurposing a familiar drug to tackle one of neurology’s most urgent emergencies.
References
[1] Manavi, M.A., Toutounchian, S., Afsahi, S. et al. Ivermectin Exerts Anticonvulsant Effects Against Status Epilepticus Induced by Lithium-Pilocarpine in Rats via GABAA Receptor and Neuroinflammation Modulation: Possible Interaction of Opioidergic Pathways and KATP Channel with Nitrergic System. Mol Neurobiol 61, 7627–7638 (2024). https://doi.org/10.1007/s12035-024-04061-3